Further targets that are currently investigated include the tumour differentiation antigen mesothelin for ovarian cancer [225], TROP2 (NCT06066424, NCT05922930) [206], ROBO1 (NCT03940820, NCT03941457) [130], EGFR [97], GCP3 (gamma-Tubulin complex protein 3) for hepatocellular carcinomas [111,112,131], B7H3 for glioblastoma [100,101], and members of the claudin family for gastric and pancreatic cancers (NCT06464965, NCT05410717) [120] (see also Table 4). This evidence concerns the gene MSLN and familial pancreatic carcinoma.